How to write primary and secondary pharmacodynamics reports

How do primary and secondary pharmacodynamics reports differ?

Primary pharmacodynamics reports address effects related to the intended therapeutic target or mode of action. Secondary pharmacodynamics reports examine other pharmacodynamic effects. Write each report around its experimental objective, measured response and limitations; the assay name alone does not establish its role or prove clinical efficacy.

Before you begin

Preparation of acquired nonclinical pharmacology evidence, including in vitro and in vivo reports. Study selection remains product-specific.

What you will prepare: A traceable pharmacodynamics report with a defensible primary or secondary placement and qualified conclusions.

Classify by the question the experiment answers

The pharmacology family contains primary, secondary, safety and interaction reports. Primary pharmacodynamics addresses the intended therapeutic target; secondary pharmacodynamics addresses effects outside that intended target. Record the protocol objective before assigning 4.2.1.1 or 4.2.1.2. A “screening” title alone does not tell you which question was studied.

Where a report answers several questions, ask the nonclinical and publishing owners to agree a main location and useful cross-references. Avoid independent copies that can diverge when amended. Safety pharmacology and combination experiments have their own preparation tasks; a secondary screen is not automatically a complete safety-pharmacology assessment.

Collect enough context to interpret the response

This is an editorial evidence map, not a prescribed assay protocol. Gather the approved protocol, amendments, test-article identity and lot, test-system description, assay qualification records, concentration or dosing records, raw or processed outputs, analysis method and any deviations. For a cell experiment, identify the cell system and its relevant target characteristics. For an animal experiment, retain model, allocation, treatment, observation period and exclusions.

Keep controls and comparators visible beside the test article. A response curve without a credible control response or an identifiable analysis population is not ready for a strong mechanistic conclusion. If a collaborator supplied only slides, request the supporting report and data disposition rather than reconstructing missing methods from a figure.

Write from observation to bounded interpretation

Open with the specific experimental objective. Describe what was actually done, including changes from the planned method, then present results by assay or model with units, variability and the observations entering the analysis. Explain what the endpoints measure before discussing what they might imply.

For primary studies, distinguish target engagement, downstream activity and a disease-model outcome. These are related observations but not interchangeable demonstrations. For secondary studies, identify the tested concentration range and interpret activity relative to the limitations of that system; an untested target remains untested. Put inconclusive, inconsistent and technically compromised findings in the results discussion instead of omitting them.

A useful conclusion states the observed effect, its experimental conditions, the evidence supporting the proposed mechanism and the remaining uncertainty. Carry those qualifications into Module 2.6.2 rather than allowing the summary to overstate the report.

Review a tempting selectivity claim

Fictional example: a compound shows activity at its intended receptor, while a limited secondary panel reports no signal at one concentration. The proposed conclusion says “highly selective across all receptors.” The evidence only supports a conclusion about the evaluated panel under the stated conditions.

The reviewer should identify the panel and assay sensitivity, verify the tested exposure conditions and narrow the sentence accordingly. If the concentration record is missing, keep the comparative conclusion unresolved. A clear report describes that limitation; it does not invent a concentration or imply that an additional experiment has been completed.

Connect each pharmacological claim to the experiment that supports it

Before drafting the discussion, build a claim table from the actual experiments. The table is a writing aid: it does not select assays or set scientific acceptance criteria.

For each row, identify the figure or table that carries the result and the author who can resolve an interpretation question. If the same sentence requires two experiments, cite both and explain what each contributes. This makes a mechanistic argument reviewable without pretending that every step was measured in one assay.

Sentence exercise: replace “The study establishes a selective clinical mechanism” with a statement naming the observed target response and tested secondary panel. Add the conditions and unresolved links to clinical relevance. Do not supply a potency, exposure margin or selectivity ratio unless the controlled analysis supports it.

Check the pharmacology summaries for the same scope of conclusion. If a secondary finding raises a functional safety question, link the actual safety pharmacology report or identify the assessment as pending; do not let a cross-reference imply that follow-up has occurred.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides